“Woah! It's like Spotify but for academic articles.”

Instant Access to Thousands of Journals for just $40/month

Get 2 Weeks Free

Atypical Antipsychotics: The Two New Arrivals

Atypical Antipsychotics: The Two New Arrivals


Issues in Mental Health Nursing, 32:85–86, 2011 Copyright © Informa Healthcare USA, Inc. ISSN: 0161-2840 print / 1096-4673 online DOI: 10.3109/01612840.2010.527034 PSYCHOTHERAPEUTICS COLUMN Atypical Antipsychotics: The Two New Arrivals Edited by Marian W. Roman, PhD The University of Tennessee, College of Nursing, Knoxville, Tennessee, USA During 2009, The United States Food and Drug Administration (FDA) approved two new antipsychotic agents to be prescribed and marketed. A brief summary of the research and specific characteristics of the two newly approved atypical antipsychotics is presented. This is not an itemized review of all clinical trial data, but rather a pr´ cis for clinicians, highlighting e what these new products offer, specifically, that other medications do not. Neither medication presents a dramatic breakthrough in the treatment of the major mental illnesses they address, but each offers some amelioration of one or more of the most troublesome side effects associated with the current second generation of antipsychotics. If these improved profiles result in greater adherence to, or diminished long-term sequelae of, treatment, one or both may offer a benefit not previously available in the psychopharmacology armamentarium. SAFETY AND EFFICACY In May 2009, iloperidone (FANAPT R ) was approved. This medication is structurally
Loading next page...
Problems Reading this Article? Report Issue Here

You're reading a free preview. Subscribe to read the entire article.

And millions more from thousands of peer-reviewed journals, for only $40/month.

Get 2 Weeks Free

To be the best researcher, you need access to the best research

  • With DeepDyve, you can stop worrying about how much articles cost, or if it's too much hassle to order — it's all at your fingertips. Your research is important and deserves the top content.
  • Read from thousands of the leading scholarly journals from Springer, Elsevier, Nature, IEEE, Wiley-Blackwell and more.
  • All the latest content is available, no embargo periods.

Stop missing out on the latest updates in your field

  • We’ll send you automatic email updates on the keywords and journals you tell us are most important to you.
  • There is a lot of content out there, so we help you sift through it and stay organized.